Buy or sell Tarveda Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Tarveda Therapeutics Stock

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

About Tarveda Therapeutics Stock

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.

Funding History

January 2012$2.8M
December 2013$21.0M
March 2014$1.0M
January 2015$21.0M
January 2016$38.0M
February 2017$30.0M
December 2019$13.6M
December 2020$15.0M
September 2021$6.0M

Management

Executive Vice President, Drug Discovery

Mark Bilodeau

Founder

Stephen J. Lippard

Associate Director; Analytical and Formulation Development

Beata Sweryda-Krawiec

President and Chief Executive Officer

Brian Roberts

Board Advisor

Philip Kantoff

Chief Scientific Officer

Mark Bilodeau

Board Member

Guido Magni

Chairman

Drew Fromkin

Board Member

Robert Langer

Board Member

Aymeric Sallin

Board Member

Nilesh Kumar

Board Member

Bibhash Mukhopadhyay

Chief Medical Officer

Jeffrey Bloss

Member Board Of DirectorsMember

Michael Metzger

Board Member

Dennis Ausiello

Board Advisor

Omid Farokhzad

Executive Vice President, Strategy

Sudha Kadiyala

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 290K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo